+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Biomarkers Market Size, Share & Trends Analysis Report By Type (Safety, Efficacy), By Application (Diagnostic, Drug Discovery & Development), By Disease (CVD, Cancer), By Region, And Segment Forecasts, 2021 - 2028

  • PDF Icon

    Report

  • 145 Pages
  • September 2021
  • Region: Global
  • Grand View Research
  • ID: 5450251
The global biomarkers market size is expected to reach USD 147.59 billion by 2028, according to a new report by the publisher It is projected to register a CAGR of 14.2% over the forecast period, which is driven by increasing collaborations & funds for R&D activities, rising consumer awareness, COVID-19 pandemic, and technological advancements in disease diagnosis. Research aids in the development of effective therapies for the treatment of various diseases, such as cancer, Cardiovascular Diseases (CVDs), immunological diseases, and neurological diseases.



It has been observed that there has been an increase in public and private investments in the market. For instance, in January 2020, Johnson & Johnson Services, Inc. received a grant from Food Allergy Research & Education (FARE) worth USD 250,000 to propel the research on food allergy biomarkers. This grant is anticipated to help in the potential discovery and validation of allergy biomarkers for developing therapies. This can potentially improve the quality of life for 32 million people in the U.S. who are suffering from food allergies.

The government has also increased the funding for cancer research. For instance, in February 2020, President Trump, recently, signed a bill to fund the federal government in the U.S. along with the National Cancer Institute that received USD 6.44 billion. This funding is more than nearly USD 300 million that was allocated in 2019. These funds are expected to fuel the research associated with cancer, which is likely to have a positive impact on the market in the long run. Proactive government initiatives are driving the betterment of the reimbursement scenario in this market.

For instance, several researchers in the Asia Pacific region are involved in collaborations with regulatory authorities to validate and discover surrogate markers for use in drug development. The Japanese regulatory authorities and the government have employed a framework to promote collaborations and partnerships. Commercial insurers, generally, decide the need for biomarker testing for a patient before insuring their targeted therapy expenditures. While some insurers mandate medical evidence or prescription for biomarker testing, others may require patients to acknowledge that they are not undertaking certain therapies.

Biomarkers Market Report Highlights

  • The safety biomarkers segment accounted for the largest revenue share in 2020 due to the growing awareness about routine health checkups and rising use in the preclinical stage
  • The validation biomarkers segment is estimated to register the fastest CAGR over the forecast period due toa wide application scope in pharmaceutical companies
  • The drug discovery & development segment dominated the global market in 2020 owing to the ability to accelerate drug development in certain diseases as they can predict drug efficacy more easily than conventional clinical endpoints
  • The diagnostic segment will register the fastest CAGR over the forecast period due to the increased use of biomarkers in early-stage disease diagnosis
  • The cancer disease segment held the maximum revenue share in 2020 due to an increased prevalence of cancer and the use of biomarkers for the detection of cancer
  • CVD is estimated to be the fastest-growing disease segment over the forecast period
  • North America accounted for the maximum revenue share in 2020 due to the presence of major key players in the region and increased per capita healthcare expenditure
  • Europe, on other hand, is estimated to be the fastest-growing regional market over the forecast period


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Biomarkers Market

What is the estimated value of the Biomarkers Market?

The Biomarkers Market was estimated to be valued at $51.18 Billion in 2020.

What is the growth rate of the Biomarkers Market?

The growth rate of the Biomarkers Market is 14.2%, with an estimated value of $147.59 Billion by 2028.

What is the forecasted size of the Biomarkers Market?

The Biomarkers Market is estimated to be worth $147.59 Billion by 2028.

Who are the key companies in the Biomarkers Market?

Key companies in the Biomarkers Market include F. HOFFMANN, LA ROCHE LTD., ABBOTT LABORATORIES, EPIGENOMICS AG, GENERAL ELECTRIC, JOHNSON & JOHNSON SERVICES, INC., THERMO FISHER SCIENTIFIC, INC., BIO and SIEMENS HEALTHINEERS AG.

Table of Contents

Chapter 1 Methodology and Scope
1.1 Market Segmentation and Scope
1.1.1 Segment Scope
1.1.2 Regional Scope
1.1.3 Estimates And Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database:
1.3.2 Internal database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details Of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach: Commodity Flow Approach
1.7 Research Assumptions
1.8 List of Secondary Sources
1.9 List of Abbreviations
1.10 Objectives
1.10.1 Objective 1
1.10.2 Objective 2
1.10.3 Objective 3
1.10.4 Objective 4
Chapter 2 Executive Summary
2.1 Market Outlook
2.2 Segment Outlook
2.3 Competitive Insights
Chapter 3 Biomarkers Market Variables, Trends, and Scope
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.1.2 Ancillary Market Outlook
3.2 Penetration and Growth Prospect Mapping
3.3 Regulatory Framework
3.3.1 Reimbursement Framework
3.3.2 Standards & Compliances
3.4 User Perspective Analysis
3.4.1 Consumer Behavior Analysis
3.5 Market Dynamics
3.5.1 Market Drivers Analysis
3.5.1.1 Increasing funding for biomarkers
3.5.1.2 Increasing prevalence of chronic diseases
3.5.1.3 Technological advancements
3.5.2 Market Restraint Analysis
3.5.2.1 Lack of reimbursement policies for biomarkers treatment
3.6 Biomarkers: Market Analysis Tools
3.6.1 Industry Analysis: Porter’s
3.6.2 Pestle Analysis
3.6.3 Major Deals And Strategic Alliances
3.6.3.1 New Product Launch
3.6.3.2 Acquisition
3.6.3.3 Partnerships
3.6.3.4 Marketing & Promotions
Chapter 4 Biomarkers Market: Segment Analysis, By Type, 2017 - 2028 (USD Million)
4.1 Definition and Scope
4.2 Type Market Share Analysis, 2020 & 2028
4.3 Segment Dashboard
4.4 Global Biomarkers Market, by Type, 2017 to 2028
4.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
4.5.1 Safety
4.5.1.1 Safety biomarkers market, 2017 - 2028 (USD Million)
4.5.2 Efficacy
4.5.2.1 Efficacy biomarkers market, 2017 - 2028 (USD Million)
4.5.3 Validation
4.5.3.1 Validation biomarkers market, 2017 - 2028 (USD Million)
Chapter 5 Biomarkers Market: Segment Analysis, By Application, 2017 - 2028 (USD Million)
5.1 Definition and Scope
5.2 Application Market Share Analysis, 2020 & 2028
5.3 Segment Dashboard
5.4 Global Biomarkers Market, by Application, 2017 to 2028
5.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
5.5.1 Diagnostics
5.5.1.1 Diagnostics market, 2017 - 2028 (USD Million)
5.5.2 Drug Discovery And Development
5.5.2.1 Drug discovery and development market, 2017 - 2028 (USD Million)
5.5.2.2 Preclinical trials
5.5.2.2.1 Introduction
5.5.2.2.2 Application
5.5.2.2.3 Regulations
5.5.2.2.4 Therapeutic gap in preclinical and clinical trial
5.5.2.2.5 Regional overview
5.5.2.2.6 Preclinical trials market, 2017- 2028 (USD Million)
5.5.2.3 Clinical trials
5.5.2.3.1 Clinical trials market, 2017- 2028 (USD Million)
5.5.3 Personalized Medicine
5.5.3.1 Personalized medicine market, 2017 - 2028 (USD Million)
5.5.4 Others
5.5.4.1 Others market, 2017 - 2028 (USD Million)
Chapter 6 Biomarkers Market: Segment Analysis, By Diseases, 2017 - 2028 (USD Million)
6.1 Definition and Scope
6.2 Diseases Market Share Analysis, 2020 & 2028
6.3 Segment Dashboard
6.4 Global Biomarkers Market, by Diseases, 2020 to 2028
6.5 Market Size & Forecasts and Trend Analyses, 2017 to 2028
6.5.1 Cancer
6.5.1.1 Cancer biomarkers market, 2017 - 2028 (USD Million)
6.5.2 Cardiovascular Diseases
6.5.2.1 Cardiovascular disease biomarkers market, 2017 - 2028 (USD Million)
6.5.3 Neurological Diseases
6.5.3.1 Neurological disease biomarkers market, 2017 - 2028 (USD Million)
6.5.4 Immunological Diseases
6.5.4.1 Immunological disease biomarkers market, 2017 - 2028 (USD Million)
6.5.5 Others
6.5.5.1 Other biomarkers market, 2017 - 2028 (USD Million)
Chapter 7 Biomarkers Market: Segment Analysis, By Region, 2017 - 2028 (USD Million)
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2020 & 2028
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 Regional Market Share and Leading Players, 2020
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 Middle East And Africa
7.6 Swot Analysis
7.6.1 North America
7.6.2 Europe
7.6.3 Asia Pacific
7.6.4 Latin America
7.6.5 Middle East And Africa
7.7 Market Size, & Forecasts, Revenue and Trend Analysis, 2020 to 2028
7.7.1 North America
7.7.1.1 North America market estimates and forecast, 2017 - 2028 (USD Million)
7.7.1.2 U.S.
7.7.1.2.1 U.S. biomarkers market, 2017 - 2028 (USD Million)
7.7.1.3 Canada
7.7.1.3.1 Canada biomarkers market, 2017 - 2028 (USD Million)
7.7.2 Europe
7.7.2.1 Europe biomarkers market, 2017 - 2028 (USD Million)
7.7.2.2 U.K.
7.7.2.2.1 U.K. biomarkers market, 2017 - 2028 (USD Million)
7.7.2.3 Germany
7.7.2.3.1 Germany biomarkers market, 2017 - 2028 (USD Million)
7.7.2.4 Spain
7.7.2.4.1 Spain biomarkers market, 2017 - 2028 (USD Million)
7.7.2.5 France
7.7.2.5.1 France biomarkers market, 2017 - 2028 (USD Million)
7.7.2.6 Italy
7.7.2.6.1 Italy biomarkers market, 2017 - 2028 (USD Million)
7.7.3 Asia Pacific
7.7.3.1 Asia Pacific biomarkers market, 2017 - 2028 (USD Million)
7.7.3.2 Japan
7.7.3.2.1 Japan biomarkers market, 2017 - 2028 (USD Million)
7.7.3.3 China
7.7.3.3.1 China biomarkers market, 2017 - 2028 (USD Million)
7.7.3.4 India
7.7.3.4.1 India biomarkers market, 2017 - 2028 (USD Million)
7.7.3.5 South Korea
7.7.3.5.1 South Korea biomarkers market, 2017 - 2028 (USD Million)
7.7.3.6 Australia
7.7.3.6.1 Australia biomarkers market, 2017 - 2028 (USD Million)
7.7.4 Latin America
7.7.4.1 Latin America biomarkers market, 2017 - 2028 (USD Million)
7.7.4.2 Brazil
7.7.4.2.1 Brazil biomarkers market, 2017 - 2028 (USD Million)
7.7.4.3 Mexico
7.7.4.3.1 Mexico biomarkers market, 2017 - 2028 (USD Million)
7.7.4.4 Argentina
7.7.4.4.1 Argentina biomarkers market, 2017 - 2028 (USD Million)
7.7.5 MEA
7.7.5.1 MEA biomarkers market, 2017 - 2028 (USD Million)
7.7.5.2 South Africa
7.7.5.2.1 South Africa biomarkers market, 2017 - 2028 (USD Million)
7.7.5.3 Saudi Arabia
7.7.5.3.1 Saudi Arabia biomarkers market, 2017 - 2028 (USD Million)
7.7.5.4 UAE
7.7.5.4.1 UAE biomarkers market, 2017 - 2028 (USD Million)
Chapter 8 Biomarkers Market: Competitive Analysis
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 Ansoff Matrix
8.1.2 Heat Map Analysis
8.2 Company Categorization
8.2.1 Innovators
8.2.2 Market Leaders
8.3 Vendor Landscape
8.3.1 List Of Key Distributors And Channel Partners
8.3.2 Key Customers
8.3.3 Key Company Market Share Analysis, 2020
8.4 Public Companies
8.4.1 Company Market Position Analysis
8.4.2 Company Market Position Analysis
8.4.3 Company Market Share, By Region
8.4.4 Competitive Dashboard Analysis
8.4.4.1 Market Differentiators
8.5 Private Companies
8.5.1 List Of Key Emerging Companies
8.6 Company Profiles
8.6.1 F. HOFFMANN-LA ROCHE LTD.
8.6.1.1 Company overview
8.6.1.2 Financial performance
8.6.1.3 Product benchmarking
8.6.1.4 Strategic initiatives
8.6.2 ABBOTT LABORATORIES
8.6.2.1 Company overview
8.6.2.2 Financial performance
8.6.2.3 Product benchmarking
8.6.2.4 Strategic initiatives
8.6.3 EPIGENOMICS AG
8.6.3.1 Company overview
8.6.3.2 Financial performance
8.6.3.3 Product benchmarking
8.6.3.4 Strategic initiatives
8.6.4 GENERAL ELECTRIC
8.6.4.1 Company overview
8.6.4.2 Financial performance
8.6.4.3 Product benchmarking
8.6.4.4 Strategic initiatives
8.6.5 JOHNSON & JOHNSON SERVICES, INC.
8.6.5.1 Company overview
8.6.5.2 Financial performance
8.6.5.3 Product benchmarking
8.6.5.4 Strategic initiatives
8.6.6 THERMO FISHER SCIENTIFIC, INC.
8.6.6.1 Company overview
8.6.6.2 Financial performance
8.6.6.3 Product benchmarking
8.6.6.4 Strategic initiatives
8.6.7 BIO-RAD LABORATORIES, INC.
8.6.7.1 Company overview
8.6.7.2 Financial performance
8.6.7.3 Product benchmarking
8.6.7.4 Strategic initiatives
8.6.8 SIEMENS HEALTHINEERS AG
8.6.8.1 Company overview
8.6.8.2 Financial performance
8.6.8.3 Product benchmarking
8.6.8.4 Strategic initiatives
8.6.9 QIAGEN
8.6.9.1 Company overview
8.6.9.2 Financial performance
8.6.9.3 Product benchmarking
8.6.9.4 Strategic initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Estimated new cancer case statistics 2012 & 2018
Table 4 Role of preclinical biomarkers and their impact on business
Table 5 Key preclinical biomarker applications in animals
Table 6 Regional overview of preclinical biomarkers
Table 7 Global Biomarkers, By Region, 2017 - 2028 (USD Million)
Table 8 Global Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 9 Global Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 10 Global Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 11 North America Biomarkers, By Country, 2017 - 2028 (USD Million)
Table 12 North America Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 13 North America Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 14 North America Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 15 U.S. Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 16 U.S. Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 17 U.S. Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 18 Canada Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 19 Canada Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 20 Canada Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 21 Europe Biomarkers, By Country, 2017 - 2028 (USD Million)
Table 22 Europe Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 23 Europe Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 24 Europe Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 25 Germany Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 26 Germany Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 27 Germany Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 28 U.K. Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 29 U.K. Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 30 U.K. Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 31 France Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 32 France Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 33 France Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 34 Italy Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 35 Italy Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 36 Italy Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 37 Spain Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 38 Spain Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 39 Spain Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 40 Asia Pacific Biomarkers, By Country, 2017 - 2028 (USD Million)
Table 41 Asia Pacific Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 42 Asia Pacific Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 43 Asia Pacific Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 44 Japan Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 45 Japan Biomarkers, By Application 2017 - 2028 (USD Million)
Table 46 Japan Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 47 China Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 48 China Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 49 China Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 50 India Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 51 India Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 52 India Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 53 Australia Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 54 Australia PCR Market, By Application, 2017 - 2028 (USD Million)
Table 55 Australia Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 56 South Korea Biomarkers, By Type 2017 - 2028 (USD Million)
Table 57 South Korea Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 58 South Korea Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 59 Latin America Biomarkers, By Country, 2017 - 2028 (USD Million)
Table 60 Latin America Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 61 Latin America Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 62 Latin America Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 63 Brazil Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 64 Brazil Biomarkers, By Application 2017 - 2028 (USD Million)
Table 65 Brazil Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 66 Mexico Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 67 Mexico Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 68 Mexico Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 69 Argentina Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 70 Argentina Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 71 Argentina Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 72 Middle East & Africa Biomarkers, By Country, 2017 - 2028 (USD Million)
Table 73 Middle East & Africa Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 74 Middle East & Africa Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 75 Middle East & Africa Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 76 Saudi Arabia Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 77 Saudi Arabia Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 78 Saudi Arabia Biomarkers, By Disease , 2017 - 2028 (USD Million)
Table 79 South Africa Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 80 South Africa Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 81 South Africa Biomarkers, By Disease, 2017 - 2028 (USD Million)
Table 82 UAE Biomarkers, By Type, 2017 - 2028 (USD Million)
Table 83 UAE Biomarkers, By Application, 2017 - 2028 (USD Million)
Table 84 UAE Biomarkers, By Disease, 2017 - 2028 (USD Million)
List of Figures
Figure. 1 Biomarkers market segmentation
Figure. 2 Market research process
Figure. 3 Information procurement
Figure. 4 Primary research pattern
Figure. 5 Market research approaches
Figure. 6 Value-chain-based sizing & forecasting
Figure. 7 QFD modeling for market share assessment
Figure. 8 Market formulation & validation
Figure. 9 Market outlook (2020)
Figure. 10 Segment Outlook (Disease Type, 2020)
Figure. 11 Strategy framework
Figure. 12 Penetration & growth prospect mapping
Figure. 13 Consumer behavior analysis
Figure. 14 Market driver relevance analysis (Current & future impact)
Figure. 15 Market restraint relevance analysis (Current & future impact)
Figure. 16 Porter’s five forces analysis
Figure. 17 PESTLE analysis
Figure. 18 Strategy mapping
Figure. 19 Biomarkers market: Type movement analysis
Figure. 20 Type segment dashboard
Figure. 21 Biomarkers market type outlook: Key takeaways
Figure. 22 Safety biomarkers market, 2017 - 2028 (USD million)
Figure. 23 Efficacy biomarkers market, 2017 - 2028 (USD million)
Figure. 24 Validation biomarkers market, 2017 - 2028 (USD million)
Figure. 25 Biomarkers market: Application movement analysis
Figure. 26 Application segment dashboard
Figure. 27 Biomarkers application outlook: Key takeaways
Figure. 28 Diagnostics market, 2017 - 2028 (USD million)
Figure. 29 Drug discovery & development market, 2017 - 2028 (USD million)
Figure. 30 Preclinical trials market, 2017 - 2028 (USD million)
Figure. 31 Clinical trials market, 2017 - 2028 (USD million)
Figure. 32 Personalized market, 2017 - 2028 (USD million)
Figure. 33 Others market, 2017 - 2028 (USD million)
Figure. 34 Biomarkers market: Diseases movement analysis
Figure. 35 Diseases segment dashboard
Figure. 36 Biomarkers market sales channel outlook: Key takeaways
Figure. 37 Cancer biomarkers market, 2017 - 2028 (USD million)
Figure. 38 Cardiovascular disease biomarkers market, 2017 - 2028 (USD million)
Figure. 39 Neurological disease biomarkers market, 2017 - 2028 (USD million)
Figure. 40 Immunological disease biomarkers market, 2017 - 2028 (USD million)
Figure. 41 Other biomarkers market, 2017 - 2028 (USD million)
Figure. 42 Regional outlook, 2020 & 2028
Figure. 43 Regional market dashboard
Figure. 44 Regional marketplace: Key takeaways
Figure. 45 North America market share and key players (2020)
Figure. 46 Europe market share and key players (2020)
Figure. 47 Asia Pacific market share and key players (2020)
Figure. 48 Latin America market share and key players (2020)
Figure. 49 Middle East and Africa market share and key players (2020)
Figure. 50 North America, SWOT
Figure. 51 Europe, SWOT
Figure. 52 Asia Pacific, SWOT
Figure. 53 Latin America, SWOT
Figure. 54 Middle East and Africa, SWOT
Figure. 55 North America
Figure. 56 North America biomarkers market, 2017 - 2028 (USD Million)
Figure. 57 U.S.
Figure. 58 U.S. biomarkers market, 2017 - 2028 (USD Million)
Figure. 59 Canada
Figure. 60 Canada biomarkers market, 2017 - 2028 (USD Million)
Figure. 61 Europe
Figure. 62 Europe biomarkers market, 2017 - 2028 (USD Million)
Figure. 63 U.K.
Figure. 64 U.K. biomarkers market, 2017 - 2028 (USD Million)
Figure. 65 Germany
Figure. 66 Germany biomarkers market, 2017 - 2028 (USD Million)
Figure. 67 Spain
Figure. 68 Spain biomarkers market, 2017 - 2028 (USD Million)
Figure. 69 France
Figure. 70 France biomarkers market, 2017 - 2028 (USD Million)
Figure. 71 Italy
Figure. 72 Italy biomarkers market, 2017 - 2028 (USD Million)
Figure. 73 Asia Pacific
Figure. 74 Asia Pacific biomarkers market, 2017 - 2028 (USD Million)
Figure. 75 Japan
Figure. 76 Japan biomarkers market, 2017 - 2028 (USD Million)
Figure. 77 China
Figure. 78 China biomarkers market, 2017 - 2028 (USD Million)
Figure. 79 India
Figure. 80 India biomarkers market, 2017 - 2028 (USD Million)
Figure. 81 South Korea
Figure. 82 South Korea biomarkers market, 2017 - 2028 (USD Million)
Figure. 83 Australia
Figure. 84 Australia biomarkers market, 2017 - 2028 (USD Million)
Figure. 85 Latin America
Figure. 86 Latin America biomarkers market, 2017 - 2028 (USD Million)
Figure. 87 Brazil
Figure. 88 Brazil biomarkers market, 2017 - 2028 (USD Million)
Figure. 89 Mexico
Figure. 90 Mexico biomarkers market, 2017 - 2028 (USD Million)
Figure. 91 Argentina
Figure. 92 Argentina biomarkers market, 2017 - 2028 (USD Million)
Figure. 93 Middle East and Africa
Figure. 94 MEA biomarkers market, 2017 - 2028 (USD Million)
Figure. 95 South Africa
Figure. 96 South Africa biomarkers market, 2017 - 2028 (USD Million)
Figure. 97 Saudi Arabia
Figure. 98 Saudi Arabia biomarkers market, 2017 - 2028 (USD Million)
Figure. 99 UAE
Figure. 100 UAE biomarkers market, 2017 - 2028 (USD Million)
Figure. 101 Ansoff Matrix
Figure. 102 Heat map analysis
Figure. 103 Company market share analysis
Figure. 104 Company market position analysis (2020)
Figure. 105 Company market position analysis (2020)
Figure. 106 Company market share, by region
Figure. 107 Market differentiators

Companies Mentioned

  • F. HOFFMANN-LA ROCHE LTD.
  • ABBOTT LABORATORIES
  • EPIGENOMICS AG
  • GENERAL ELECTRIC
  • JOHNSON & JOHNSON SERVICES, INC.
  • THERMO FISHER SCIENTIFIC, INC.
  • BIO-RAD LABORATORIES, INC.
  • SIEMENS HEALTHINEERS AG
  • QIAGEN

Methodology

Loading
LOADING...